Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A STAR), Singapore.
Eur J Immunol. 2010 Mar;40(3):638-42. doi: 10.1002/eji.200940039.
Alum has been the only adjuvant licensed for human vaccines for decades and is still widely used, but its mechanism of action remains obscure. Recently, the NLRP3 inflammasome has been linked to the immunostimulatory properties of alum and other particulate adjuvants, although it is disputed to what degree NLRP3 is genuinely essential in vivo. Meanwhile, researchers are testing adjuvants harnessing both the infectious/non-infectious-discriminating TLR and the danger-sensing NLRP3 inflammasome pathways. Could this be the basis of a long-needed rationale in the design of adjuvants?
明矾几十年来一直是唯一获得许可用于人类疫苗的佐剂，并且仍被广泛使用，但它的作用机制仍然不清楚。最近，NLRP3 炎性小体与明矾和其他颗粒佐剂的免疫刺激特性有关，尽管 NLRP3 在体内的真正重要性存在争议。与此同时，研究人员正在测试利用 TLR 识别感染/非感染以及 NLRP3 炎性小体感应危险这两条途径的佐剂。这是否可以成为设计佐剂方面长期以来所需要的基本原理的基础？
